{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:37:15Z","timestamp":1787762235552,"version":"build-2784847793"},"reference-count":114,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.idc.2009.06.010","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T05:35:33Z","timestamp":1258004133000},"page":"965-982","source":"Crossref","is-referenced-by-count":38,"title":["Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin\/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael D.","family":"Nailor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.010_bib1","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1093\/clinids\/3.Supplement.S205","article-title":"Structural features of vancomycin","volume":"Nov\u2013Dec","author":"Pfeiffer","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.010_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","article-title":"Vancomycin: a 50-year reassessment","volume":"42","author":"Moellering","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl 24","key":"10.1016\/j.idc.2009.06.010_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/1841894b0","article-title":"Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin","volume":"184","author":"Jordan","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.idc.2009.06.010_bib4","first-page":"489","article-title":"Site of action of vancomycin on Staphylococcus aureus","volume":"4","author":"Jordan","year":"1964","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.010_bib5","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1093\/clinids\/3.Supplement.S269","article-title":"Pharmacokinetics of vancomycin in anuria","volume":"Nov\u2013Dec","author":"Cunha","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997\u20132002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.22.5.903","article-title":"Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains","volume":"22","author":"Watanakunakorn","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-98-4-447","article-title":"Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observation as a guide to therapy","volume":"98","author":"Karchmer","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2009.06.010_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical application to the use of \u00df-lactam, glycopeptides and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2009.06.010_bib10","first-page":"261","article-title":"Vancomycin therapy of bacterial meningitis","volume":"126","author":"Hawley","year":"1973","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.idc.2009.06.010_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical pharmacokinetics of vancomycin","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharm"},{"key":"10.1016\/j.idc.2009.06.010_bib12","first-page":"638","article-title":"Cerebrospinal fluid penetration of vancomycin in bacterial meningitis","volume":"vol. 1","author":"Redfield","year":"1980"},{"key":"10.1016\/j.idc.2009.06.010_bib13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.32.9.1320","article-title":"Vancomycin concentrations in infected and non-infected human bone","volume":"32","author":"Graziani","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lung fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib15","first-page":"172","article-title":"Antibiotic therapy of bacterial endocarditis: VII. Vancomycin for acute micrococcal endocarditis: preliminary report","volume":"33","author":"Geraci","year":"1958","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"10.1016\/j.idc.2009.06.010_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jac\/5.4.475","article-title":"Vancomycin concentration in human tissues: preliminary report","volume":"5","author":"Torres","year":"1979","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/j.1875-9114.1988.tb04084.x","article-title":"Evaluation of a method for initiating vancomycin therapy. Experience in 205 patients","volume":"8","author":"Lake","year":"1988","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2009.06.010_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-94-3-343","article-title":"Vancomycin therapy in patients with impaired renal function: a nomogram for dosage","volume":"94","author":"Moellering","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2009.06.010_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idc.2009.06.010_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idc.2009.06.010_bib22","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3476(80)80347-7","article-title":"Clinical pharmacology and efficacy of vancomycin in pediatric patients","volume":"96","author":"Schaad","year":"1980","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.idc.2009.06.010_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-100-4-533","article-title":"Systemic absorption on enteral vancomycin in a patient with pseudomembranous colitis","volume":"100","author":"Spitzer","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2009.06.010_bib25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(78)91741-5","article-title":"Oral vancomycin for pseudomembranous colitis","volume":"2","author":"Tedesco","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2009.06.010_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0272-6386(87)80026-4","article-title":"Once weekly intraperitoneal therapy for gram-positive peritonitis","volume":"4","author":"Morse","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1525-139X.2007.00333.x","article-title":"Vancomycin use in patients requiring hemodialysis: a literature review","volume":"21","author":"Pallotta","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.idc.2009.06.010_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3201\/eid0402.980211","article-title":"Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future","volume":"4","author":"Huycke","year":"1998","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","article-title":"Vancomycin for Staphylococcus aureus endocarditis in intravenous drug abusers","volume":"34","author":"Small","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jac\/19.2.249","article-title":"Intraventricular vancomycin for treatment of shunt-associated ventriculitis","volume":"19","author":"Swayne","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.010_bib31","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1093\/clinids\/3.Supplement.S289","article-title":"Vancomycin for treatment of bacterial meningitis","volume":"Nov\u2013Dec","author":"Gump","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib32","first-page":"597","article-title":"Nosocomial enterococci resistant to vancomycin\u2014United States, 1989\u20131993","volume":"42","author":"National Nosocomial Infections Surveillance System (NNIS)","year":"1993","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.idc.2009.06.010_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/28.1.1","article-title":"The enterococcus: a classic example of antimicrobial resistance on therapeutic options","volume":"28","author":"Moellering","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1574-6968.1992.tb05089.x","article-title":"Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus","volume":"72","author":"Noble","year":"1992","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.idc.2009.06.010_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0140-6736(93)91285-T","article-title":"Emergence of vancomycin-resistant enterococci in New York City","volume":"342","author":"Frieden","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2009.06.010_bib36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0891-5520(05)70361-5","article-title":"Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures","volume":"11","author":"Boyce","year":"1997","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2009.06.010_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-135-3-200108070-00009","article-title":"The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units","volume":"135","author":"Fridkin","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2009.06.010_bib38","article-title":"Preventing the spread of vancomycin resistance\u2014report from the Hospital Infection Control Practices Advisory Committee","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"Federal Register"},{"key":"10.1016\/j.idc.2009.06.010_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.269.5.598","article-title":"The epidemiology of intravenous vancomycin usage in a university hospital","volume":"269","author":"Ena","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2009.06.010_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1128\/JCM.37.1.39-44.1999","article-title":"Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy","volume":"37","author":"Sieradzki","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.010_bib41","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin\u2013intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib44","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.010_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib46","unstructured":"Nailor MD, Zhao JJ, Salimnia H. Daptomycin for methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations [abstract]. IDSA\/ICAAC: K3488, 2008."},{"key":"10.1016\/j.idc.2009.06.010_bib47","first-page":"624","article-title":"Reduced susceptibility of Staphylococcus aureus to vancomycin\u2014Japan, 1996","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.idc.2009.06.010_bib48","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2009.06.010_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2009.06.010_bib50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib52","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986\u20132007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"14","key":"10.1016\/j.idc.2009.06.010_bib53","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2009.06.010_bib54","unstructured":"Centers for Disease Control and Prevention Public Health Dispatch: vancomycin-resistant Staphylococcus aureus\u2014Pennsylvania, 2002. 51(40), 2002."},{"key":"10.1016\/j.idc.2009.06.010_bib55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/157.3.502","article-title":"Vancomycin and the red man syndrome: pharmacodynamics of histamine release","volume":"157","author":"Polk","year":"1988","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.010_bib56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/16.2.235","article-title":"A prospective study of adverse reactions associated with vancomycin therapy","volume":"16","author":"Sorrell","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib57","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses are associated with an increased incidence of nephrotoxicitiy","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib58","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0002-9343(86)90407-9","article-title":"Agranulocytosis related to vancomycin therapy","volume":"81","author":"Adrouny","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2009.06.010_bib59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-88-6-813","article-title":"Vancomycin revisited","volume":"88","author":"Cook","year":"1978","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.idc.2009.06.010_bib60","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0891-5520(05)70258-0","article-title":"Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin\/dalfopristin and linezolid","volume":"14","author":"Lundstrom","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2009.06.010_bib61","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/106002809502901013","article-title":"Quinupristin\/dalfopristin (RP 59500): a new streptogramin antibiotic","volume":"29","author":"Chant","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2009.06.010_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/joc.1996.8.2.107","article-title":"RP 59500, a streptogramin derivative, is effective in murine listeriosis","volume":"8","author":"Nichterlein","year":"1996","journal-title":"J Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0732-8893(98)80002-3","article-title":"Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada","volume":"30","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000239542","article-title":"In vitro activity of quinupristin\/dalfopristin, RP 59500, against gram-positive clinical isolates","volume":"43","author":"Hussain Qadri","year":"1997","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idc.2009.06.010_bib65","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Schulin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib66","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/AAC.42.10.2752","article-title":"In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci","volume":"42","author":"Struwig","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/516895","article-title":"Therapy with RP 59500 (quinupristin\/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA\/VanB resistance patterns","volume":"25","author":"Furlong","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/clinids\/24.1.91","article-title":"Superinfection with Enterococcus faecalis during quinupristin\/dalfopristin therapy","volume":"24","author":"Chow","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib69","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/380125","article-title":"Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology","volume":"38","author":"Hershberger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib70","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/clinids\/24.1.90","article-title":"Emergence of increased resistance to quinupristin\/dalfopristin during therapy for Enterococcus faecium bacteremia","volume":"24","author":"Chow","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib71","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.42.10.2710","volume":"42","author":"Aeschlimann","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s000180050429","article-title":"Oxazolidinones: a novel class of antibiotics","volume":"56","author":"Muller","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.idc.2009.06.010_bib73","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/jm980274l","article-title":"Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazine, or triazene heteroaromatic ring","volume":"41","author":"Tucker","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.idc.2009.06.010_bib74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","article-title":"Linezolid","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2009.06.010_bib75","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2009.06.010_bib76","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0732-8893(99)00016-4","article-title":"In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae","volume":"34","author":"Patel","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib78","unstructured":"Pawsey SD, Dalry-Yates PT, Wajszczuk CP, et\u00a0al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. In: Program and abstracts of the first European Congress of Infections [abstract]. Berlin. sy13.4, 1997."},{"key":"10.1016\/j.idc.2009.06.010_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement","volume":"50","author":"Lovering","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib80","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","article-title":"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose","volume":"47","author":"Wagenlehner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib81","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jac\/dkf192","article-title":"Virulence factor expression by gram-positive cocci exposed to subinhibitory concentrations of linezolid","volume":"50","author":"Gemmell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib82","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/517221","article-title":"Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin","volume":"28","author":"Noskin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib83","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib84","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.124.5.1789","article-title":"Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.idc.2009.06.010_bib85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib86","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkf215","article-title":"The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin","volume":"50","author":"Moise","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.010_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/380449","article-title":"Treating foot infections in diabetic patients: a randomized, multicenter; open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate","volume":"38","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18553\/jmcp.2003.9.4.317","article-title":"Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections","volume":"9","author":"Parodi","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.idc.2009.06.010_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01.CCM.0000104110.74657.25","article-title":"Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin","volume":"32","author":"Shorr","year":"2004","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.idc.2009.06.010_bib90","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/109629603764655290","article-title":"Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial","volume":"4","author":"Li","year":"2003","journal-title":"Surg Infect"},{"key":"10.1016\/j.idc.2009.06.010_bib91","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/jm9509556","article-title":"Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections","volume":"39","author":"Brickner","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.idc.2009.06.010_bib92","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activities of oxazolidinone compounds U-100592 and U-100766 against staphylococcus species","volume":"40","author":"Kaatz","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib93","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1086\/374929","article-title":"Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid","volume":"36","author":"Rahim","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/380465","article-title":"Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: lessons learned","volume":"38","author":"Schwartz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib95","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib96","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib97","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1086\/379327","article-title":"Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use","volume":"37","author":"Nasraway","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0196-4399(02)80007-1","article-title":"Daptomycin: a novel lipopeptide antibiotic","volume":"24","author":"Thorne","year":"2002","journal-title":"Clin Microbiol Newslett"},{"key":"10.1016\/j.idc.2009.06.010_bib99","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkg130","article-title":"Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000\u20132001","volume":"51","author":"Critchley","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkg091","article-title":"Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials","volume":"51","author":"Pankuch","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib102","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jac\/47.3.364","article-title":"Daptomycin for line-related Leuconostoc bacteremia","volume":"47","author":"Golan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib103","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1128\/AAC.01455-06","article-title":"Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed with time-kill methodology","volume":"51","author":"Credito","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib104","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/AAC.33.8.1198","article-title":"In vitro post-antibiotic effect of daptomycin (LY-146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains","volume":"33","author":"Bush","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib105","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.idc.2009.06.010_bib106","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","article-title":"Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin","volume":"50","author":"Sakoulas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/107662903322762833","article-title":"In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium","volume":"9","author":"Jevitt","year":"2003","journal-title":"Microb Drug Resist"},{"issue":"11","key":"10.1016\/j.idc.2009.06.010_bib108","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/504084","article-title":"An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"42","author":"Patel","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.06.010_bib109","unstructured":"Fairfax MR, Nailor MD, Painter T. et\u00a0al. Vancomycin and daptomycin susceptibility testing of Staphylococcus aureus in a clinical laboratory. IDSA\/ICAAC C1\u2013140, 2008."},{"key":"10.1016\/j.idc.2009.06.010_bib110","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchil","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.010_bib111","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","article-title":"Dalbavancin: a new lipoglycopeptide antibiotic","volume":"65","author":"Bailey","year":"2008","journal-title":"Am J\u00a0Health Syst Pharm"},{"key":"10.1016\/j.idc.2009.06.010_bib112","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1345\/aph.1G158","article-title":"Dalbavancin: a new option for the treatment of gram-positive infections","volume":"40","author":"Lin","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2009.06.010_bib113","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idc.2009.06.010_bib114","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","article-title":"Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections","volume":"27","author":"Drew","year":"2007","journal-title":"Pharmacotherapy"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T15:46:18Z","timestamp":1710690378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552009000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0891552009000555"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2009.06.010","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}